AR111410A1 - Combinación sinérgica de oligonucleótidos de ácidos nucleicos y agentes quimioterapéuticos inhibidores de proteína quinasas - Google Patents

Combinación sinérgica de oligonucleótidos de ácidos nucleicos y agentes quimioterapéuticos inhibidores de proteína quinasas

Info

Publication number
AR111410A1
AR111410A1 ARP180100851A ARP180100851A AR111410A1 AR 111410 A1 AR111410 A1 AR 111410A1 AR P180100851 A ARP180100851 A AR P180100851A AR P180100851 A ARP180100851 A AR P180100851A AR 111410 A1 AR111410 A1 AR 111410A1
Authority
AR
Argentina
Prior art keywords
splice variant
nucleic acid
chemotherapeutic agents
gene
protein kinases
Prior art date
Application number
ARP180100851A
Other languages
English (en)
Inventor
Shikha Saini
Fei Yue
Aditi Mathur
Sidney Hopps
Bellur Prabhakar
Original Assignee
Jivana Biotechnology Inc
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jivana Biotechnology Inc, Univ Illinois filed Critical Jivana Biotechnology Inc
Publication of AR111410A1 publication Critical patent/AR111410A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones y métodos para tratar cánceres, que comprenden administrar una combinación de agentes antineoplásicos, donde la combinación comprende agentes quimioterapéuticos inhibidores de proteína quinasas y una o más moléculas de ácidos nucleicos capaces de regular negativamente la expresión de al menos una variante de empalme del gen IG20, donde no todas las variantes de empalme del gen IG20 son reguladas negativamente. En una forma de realización, la variante de empalme del gen IG20 es una variante de empalme MADD y las moléculas de ácidos nucleicos son siARN, ARNhc y oligonucleótidos antisentido que comprenden una secuencia de ácido nucleico complementaria de la secuencia de ácido nucleico del exón 13L de la variante de empalme MADD o un transcripto de ARNm del exón 13L de la variante de empalme MADD. Métodos para tratar cánceres donde se aplica una terapia combinada con moléculas de ácidos nucleicos capaces de regular negativamente la expresión de al menos una variante de empalme del gen IG20 y agentes quimioterapéuticos inhibidores de proteína quinasas.
ARP180100851A 2017-04-24 2018-04-05 Combinación sinérgica de oligonucleótidos de ácidos nucleicos y agentes quimioterapéuticos inhibidores de proteína quinasas AR111410A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762489050P 2017-04-24 2017-04-24

Publications (1)

Publication Number Publication Date
AR111410A1 true AR111410A1 (es) 2019-07-10

Family

ID=63919941

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100851A AR111410A1 (es) 2017-04-24 2018-04-05 Combinación sinérgica de oligonucleótidos de ácidos nucleicos y agentes quimioterapéuticos inhibidores de proteína quinasas

Country Status (3)

Country Link
AR (1) AR111410A1 (es)
TW (1) TW201902487A (es)
WO (1) WO2018200149A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004012769A1 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California Therapeutic inhibitionof protein kinases in cancer cells
WO2007084954A2 (en) * 2006-01-19 2007-07-26 The Board Of Trustees Of The University Of Illinois Selective inhibition of ig20 splice variants to treat cancers
WO2010006239A2 (en) * 2008-07-10 2010-01-14 The Board Of Trustees Of The University Of Illinois Regulation of apoptosis by neural specific splice variants of ig20

Also Published As

Publication number Publication date
WO2018200149A1 (en) 2018-11-01
TW201902487A (zh) 2019-01-16

Similar Documents

Publication Publication Date Title
MX2018013157A (es) Analogos de oligonucleotidos dirigidos a lmna humana.
CO2020001354A2 (es) Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia un arni, por ejemplo, un ácido ribonucleico de hebra doble (arnhd), composiciones dirigidas al gen serpinc1 y métodos para usar dicho arni, por ejemplo, arnhd, composiciones para tratar un evento de sangrado en un sujeto que tiene una hemofilia (por ejemplo, con o sin inhibidores).
CL2017001956A1 (es) Oligomeros antisentido de tau y uso de los mismos
CY1122583T1 (el) Αναστολεις πρωτεασωματος για αντιμετωπιση μιας διαταραχης η οποια σχετιζεται με μια συσσωρευση μη-αποικοδομημενης μη-φυσιολογικης πρωτεϊνης η ενος καρκινου
CL2021002326A1 (es) Composiciones de arni contra el angiotensinógeno (agt) y métodos para su uso (divisional de solicitud n° 202002865)
AR090641A1 (es) Composiciones y metodos para inhibir la expresion del gen alas1
NZ733882A (en) Compositions for modulating c9orf72 expression
CL2020002563A1 (es) Uso de inhibidores de fubp1 para el tratamiento de infección de virus de hepatitis b
BR112017018329A2 (pt) composição para prevenir ou tratar calcificação de válvula, contendo inibidor de dpp-4
SG11201907581VA (en) Hexokinase 2-specific inhibitors for use in acute central nervous system injury
CL2021001552A1 (es) Moléculas inhibidoras de ácido nucleico de doble hebra que contienen un triloop
BR112018071031A2 (pt) combinações para o tratamento de neoplasmas utilizando o direcionamento de células-alvo inativas e inibidores de egfr
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
BR112017018198A2 (pt) inibição da atividade de olig2
MX2021013418A (es) Moleculas inhibidoras de acido nucleico bicatenario con cadenas de sentido acortadas.
AR111410A1 (es) Combinación sinérgica de oligonucleótidos de ácidos nucleicos y agentes quimioterapéuticos inhibidores de proteína quinasas
MX2022009870A (es) Ácidos ribonucleicos (arn) para la inhibición del complemento.
CL2021000018A1 (es) Oligonucleótidos para modular la expresión de rtel1
AR111587A1 (es) Combinación sinérgica de oligonucleótidos de ácidos nucleicos y agentes quimioterapéuticos alquilantes
AR111409A1 (es) Combinación sinérgica de oligonucleótidos de ácidos nucleicos y agentes quimioterapéuticos de antraciclinas
EA201792406A1 (ru) Антисмысловые олигонуклеотиды для лечения дистрофического буллезного эпидермолиза
MX2022002995A (es) Tratamiento de hidradenitis con inhibidores de quinasa.
MX2021000998A (es) Oligonucleotidos antisentido de acetil-coa carboxilasa2.
WO2019070777A3 (en) Pim kinase inhibitors in combination with autophagy inhibitors for treatment of cancers
AR111449A1 (es) Combinación sinérgica de oligonucleótidos de ácidos nucleicos y quimioterapia con taxanos

Legal Events

Date Code Title Description
FB Suspension of granting procedure